| |
| |
|
| Insider
Information: |
Kirchgraber Paul R |
| Relationship: |
CEO, Covance Drug Deve... |
| City: |
Burlington |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
12,946 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,602,664 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
12,946 |
|
|
| Total
Value |
$2,602,664 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Laboratory Corp of America |
LH |
CEO, Covance Drug Deve... |
2023-05-19 |
12,946 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-05-19 |
4 |
S |
$216.91 |
$932,707 |
D/D |
(4,300) |
12,946 |
0 |
% |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-05-19 |
4 |
OE |
$182.51 |
$784,793 |
D/D |
4,300 |
17,246 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-21 |
4 |
S |
$250.58 |
$2,004,675 |
D/D |
(8,000) |
9,069 |
0 |
% |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-21 |
4 |
OE |
$182.51 |
$547,530 |
D/D |
3,000 |
17,069 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-13 |
4 |
D |
$248.13 |
$35,234 |
D/D |
(142) |
14,069 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
483 |
14,211 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-06 |
4 |
D |
$244.50 |
$40,098 |
D/D |
(164) |
13,728 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
560 |
13,892 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-02 |
4 |
D |
$254.99 |
$35,954 |
D/D |
(141) |
13,332 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2023-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
443 |
13,473 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,007 |
13,922 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-11-01 |
4 |
D |
$222.56 |
$198,524 |
D/D |
(892) |
13,030 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-03-28 |
4 |
D |
$276.42 |
$455,540 |
D/D |
(1,648) |
11,915 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,707 |
13,563 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-14 |
4 |
D |
$272.68 |
$29,449 |
D/D |
(108) |
9,856 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
317 |
9,964 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-04 |
4 |
D |
$277.48 |
$45,784 |
D/D |
(165) |
9,647 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
560 |
9,812 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-02 |
4 |
D |
$273.18 |
$39,338 |
D/D |
(144) |
9,252 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
443 |
9,396 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-11-01 |
4 |
D |
$288.78 |
$259,324 |
D/D |
(898) |
8,953 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,007 |
9,851 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-05-06 |
4 |
S |
$276.55 |
$691,375 |
D/D |
(2,500) |
7,844 |
0 |
% |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-03-27 |
4 |
D |
$251.58 |
$198,748 |
D/D |
(790) |
9,786 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,104 |
10,576 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
